Spotlight Interview: David Esposito CEO at ONL Therapeutics in a Stimulating Conversation with PharmaShots

“Spotlight-Company of the Month” offers a unique platform for biopharma, life sciences, and healthcare companies, allowing them to connect with their target audiences and like-minded people.

This month at PharmaShots’ Spotlight, we had an opportunity to engage in conversation with David Esposito CEO at ONL Therapeutics.

David discusses the company's lead candidate ONL1204, which is a first-in-class small peptide Fas inhibitor specifically designed to fortify retinal cells from death and inflammatory signaling pathways.

ONL Therapeutics develops innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions. It is a clinical-stage biopharmaceutical company committed to helping patients see the future. The company focuses on Fas-mediated signaling that is initiated by the activation of the Fas receptor at the cell surface.

Know more about the company and its revolutionary drug candidate with our full-length Spotlight Interview!

About the Speaker:

David who is presently leading ONL therapeutics, also formerly served as the CEO of Armune Bioscience where he led the development and commercialization of blood-based diagnostics to improve the early detection of cancer (prostate cancer). Armune Bioscience was acquired by Exact Sciences (EXAS) in 2017.

David Esposito is an experienced healthcare executive who has built and scaled multiple companies that resulted in successful exits to strategic buyers.

He was President of Phadia US Inc. (allergy and autoimmune diagnostics) and played a pivotal role in the sale of the business to Thermo Fisher Scientific (TMO) in 2011. David began his career as a sales representative with Merck & Co. Inc. and rose through the ranks of sales, marketing, and commercial strategy for the US Division.

David is a combat veteran, led an infantry platoon with the 101st Airborne Division through several combat operations, and was recognized with a Bronze Star for combat action in Iraq in 1991. David earned his B.S. degree in Civil Engineering from the United States Military Academy at West Point and his MBA from Syracuse University.